NCT03486925

Brief Summary

Effects of intranasal oxytocin (24IU) on cognitive control of attention

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
71

participants targeted

Target at P50-P75 for not_applicable healthy

Timeline
Completed

Started Dec 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 19, 2017

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 27, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 3, 2018

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 20, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 28, 2018

Completed
Last Updated

March 4, 2019

Status Verified

February 1, 2019

Enrollment Period

7 months

First QC Date

March 27, 2018

Last Update Submit

February 28, 2019

Conditions

Healthy

Keywords

oxytocin, eye-tracking, attention inhibition

Outcome Measures

Primary Outcomes (2)

  • emotion-specific saccade latencies

    comparison between emotion-specific saccade latencies between the treatment groups (in milliseconds)

    45 minutes - 100 minutes after treatment

  • emotion-specific error rates

    comparison between the emotion-specific ratio of unsuccessful anti-saccades between the treatment groups.

    45 minutes - 100 minutes after treatment

Study Arms (2)

oxytocin group

EXPERIMENTAL
Drug: oxytocin treatment

placebo group

PLACEBO COMPARATOR
Drug: placebo treatment

Interventions

oxytocin treatmentDRUG

intranasal administration of oxytocin (24IU)

oxytocin group
placebo treatmentDRUG

intranasal administration of placebo

placebo group

Eligibility Criteria

Age18 Years - 30 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male, healthy participants
  • Non smokers

You may not qualify if:

  • Previous or current medical, psychiatric, neurological disorder
  • Regular medication
  • Use of any psychoactive substances in the 24 hours before experiment
  • Contra-indications for oxytocin
  • Contra-indications for eye-tracking data acquisition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

School of Life Science and Technology, University of Electronic Science and Technology of China

Chengdu, Sichuan, 611731, China

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 27, 2018

First Posted

April 3, 2018

Study Start

December 19, 2017

Primary Completion

July 20, 2018

Study Completion

August 28, 2018

Last Updated

March 4, 2019

Record last verified: 2019-02

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)